• Vaccination: Spain will administer the AstraZeneca vaccine only to people aged 18 to 55 years

  • Covid.AstraZeneca and Oxford prepare the second version of their vaccine for autumn

The coronavirus vaccine developed by AstraZeneca and the

University of Oxford

does not appear to protect against mild and moderate illness caused by the South African variant of the coronavirus, the

Financial Times


, citing a study due to be published Monday.

The pharmaceutical company has communicated that the vaccine is equally effective against the

British variant

of the coronavirus, according to new scientific evidence released this Friday.

Among the coronavirus variants that are currently of most concern to scientists and public health experts are the so-called

British, South African and Brazilian


, which appear to spread more rapidly than others.

"In this small phase I / II trial, early data have shown limited efficacy against mild disease primarily due to the South African variant B.1.351," said an AstraZeneca spokesperson in response to the FT report.

"However, we have not been able to adequately determine its effect against severe illness and hospitalization since

the subjects were predominantly healthy young adults


According to the criteria of The Trust Project

Know more

See links of interest

  • Work calendar

  • Quique San Francisco